Scholarlink

Introduction <p>Racial/ethnic minority populations in the US have a high burden of pulmonary arterial hypertension (PAH).</p> Objective <p>To evaluate demographics, disease characteristics, prescribing patterns, hospitalization, and survival in racial/ethnic groups in the SPHERE registry.</p> Methods <p>SPHERE was a US, multicenter, prospective, observational registry of adults prescribed selexipag in clinical practice (November 2016–March 2020). Follow-up was ≤ 18&#xa0;months, with data collected at routine quarterly visits.</p> Results <p>There were 759 patients with PAH: 549 (72.3%) non-Hispanic White; 117 (15.4%) Black/African American; 45 (5.9%) Hispanic; and 48 (6.3%) other/unknown race/ethnicity. Overall, 50.6% of participants had idiopathic and 27.0% had connective tissue disorder-associated PAH. Median age at diagnosis in non-Hispanic White, Black/African American, and Hispanic groups was 57, 56, and 43&#xa0;years, and at selexipag initiation was 62, 60, and 51&#xa0;years, respectively. Hispanic participants had less severe symptoms at enrollment: 40.0% had World Health Organization functional class III versus 53.4% and 50.4% of non-Hispanic White and Black/African American participants, respectively. Comorbidities were high, with some differences between groups. No notable differences existed between groups in selexipag dose or PAH-specific therapy; overall, 30.8% received monotherapy, 55.6% dual therapy, and 8.4% triple therapy before selexipag initiation. Discontinuations resulting from selexipag-related adverse events in any group were few (2.2%–7.7%). All-cause hospitalization and survival were similar across groups.</p> Conclusion <p>Selexipag was prescribed as part of combination therapy for PAH regardless of differing demographics and clinical characteristics across racial/ethnic groups, with no differences in selexipag discontinuation, hospitalization, and survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月4日

查看全文
  • Harrison W. Farber,
  • Murali M. Chakinala,
  • Anna R. Hemnes,
  • Kelly M. Chin,
  • Kristin B. Highland,
  • Vallerie V. McLaughlin,
  • Lana D. Melendres-Groves,
  • Michelle Cho,
  • Gurinderpal Doad,
  • Elham Fatehi,
  • Michelle Han,
  • Mohammad Rahman,
  • Paul Strachan,
  • Tobore Tobore,
  • Nick H. Kim

摘要

Introduction

Racial/ethnic minority populations in the US have a high burden of pulmonary arterial hypertension (PAH).

Objective

To evaluate demographics, disease characteristics, prescribing patterns, hospitalization, and survival in racial/ethnic groups in the SPHERE registry.

Methods

SPHERE was a US, multicenter, prospective, observational registry of adults prescribed selexipag in clinical practice (November 2016–March 2020). Follow-up was ≤ 18 months, with data collected at routine quarterly visits.

Results

There were 759 patients with PAH: 549 (72.3%) non-Hispanic White; 117 (15.4%) Black/African American; 45 (5.9%) Hispanic; and 48 (6.3%) other/unknown race/ethnicity. Overall, 50.6% of participants had idiopathic and 27.0% had connective tissue disorder-associated PAH. Median age at diagnosis in non-Hispanic White, Black/African American, and Hispanic groups was 57, 56, and 43 years, and at selexipag initiation was 62, 60, and 51 years, respectively. Hispanic participants had less severe symptoms at enrollment: 40.0% had World Health Organization functional class III versus 53.4% and 50.4% of non-Hispanic White and Black/African American participants, respectively. Comorbidities were high, with some differences between groups. No notable differences existed between groups in selexipag dose or PAH-specific therapy; overall, 30.8% received monotherapy, 55.6% dual therapy, and 8.4% triple therapy before selexipag initiation. Discontinuations resulting from selexipag-related adverse events in any group were few (2.2%–7.7%). All-cause hospitalization and survival were similar across groups.

Conclusion

Selexipag was prescribed as part of combination therapy for PAH regardless of differing demographics and clinical characteristics across racial/ethnic groups, with no differences in selexipag discontinuation, hospitalization, and survival.